Riskpilot← Back to searchSign inGet full accessBaMaMed AB
ABActiveOrg 5569630931Kumminvägen 36General medical practice activities · NACE 8621Est. 20141 employees
Revenue 2025
SEK 376K
+7% vs 2024
EBITDA margin
67.3%
-3% vs 2024
Equity ratio
87.7%
Financial strength
Net profit 2025
SEK 283K
+35% vs 2024
| Revenue | SEK 376K | +7% |
| EBITDA | SEK 253K | -3% |
| Net profit | SEK 283K | +35% |
| Total assets | SEK 391K | +9% |
| Equity | SEK 343K | +32% |
| Employees | 1 | — |
Legal name
BaMaMed AB
Org number
5569630931
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
25 februari 2014
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att bedriva medicinsk konsultation, utredning och behandling samt utbildning inom området, Bokföring och redovisning samt ekonomisk konsultation.
Address
Kumminvägen 36
Phone
+46708898584
Email
szoma67@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 180 | 116 | 280 | 350 | 376 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 88 | 36 | 172 | 262 | 253 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 88 | 36 | 172 | 262 | 253 |
| Net financials | — | — | 100 | 1 | 103 |
| Profit before tax | 88 | 36 | 272 | 263 | 356 |
| Tax | −19 | −7 | −35 | −54 | −73 |
| Net profit | 69 | 29 | 237 | 209 | 283 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 169 | 149 | 354 | 358 | 391 |
| Equity | 165 | 144 | 291 | 260 | 343 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4 | 5 | 63 | 98 | 48 |
| Total debt | 4 | 5 | 63 | 98 | 48 |
EBITDA margin
67.3%
This company
15.8%
Market median
+326% vs market
20212025
Equity ratio
87.7%
This company
38.2%
Market median
+130% vs market
20212025
Return on equity
82.5%
This company
18.4%
Market median
+348% vs market
20212025
Net profit margin
75.3%
This company
8.1%
Market median
+830% vs market
20212025
Asset turnover
0.96×
This company
1.12×
Market median
+14% vs market
20212025
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of BaMaMed AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Barbara Ewa Szoltysik | Deputy Board Member | 0 companies |
| Marcin Edmund Szoltysik | Board of Directors | 0 companies |